統合されたメタボロミクスと微生物群は,安定した冠動脈疾患の治療におけるSuxiao Jiuxin錠剤の互換性メカニズムを明らかにする
Wanqi Le1, Jingyu Liao1, Yuhao Zhang1
1Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No. 1200 Cai Lun Road, Pudong New District, Shanghai, 201203, China.
Chinese medicine
|September 2, 2025
まとめ
安定した冠動脈疾患 (SCAD) の患者の脂質代謝を改善します. ボルネオールはSCAD治療の重要なメカニズムであるA.ムチニフィラを豊かにすることで,クアンシオンリゾーマの吸収を高めます.
科学分野:
- 薬理学について
- メタボロミクス
- 微生物群の研究
背景:
- Suxiao Jiuxin pill (SJP) は,安定した冠動脈疾患 (SCAD) のための中国の薬です.
- SCAD治療におけるSJPの互換性メカニズムは不明である.
- この研究では,SJPがSCADの血清代謝プロファイルとその成分の相互作用を調査しています.
研究 の 目的:
- SJPで治療されたSCAD患者の血清代謝プロフィールを明らかにする.
- SJPのクアンション・リゾマとボネオルの互換性メカニズムを解読する
- SJPの治療効果におけるA.ムシニフィラの役割を調査する.
主な方法:
- SJP治療前のおよび後のSCAD患者の血清の代謝分析
- メタボロミクスと16S rRNAの配列化により,クアンション・リゾーマとボルネオルの相容性を研究する.
- マウスの体内試験で,併用による効果を評価した.
主要な成果:
- SJPはSCAD患者における脂質代謝を有意に調節し,グリセロフォスホリピドと脂肪アシルに影響を与えます.
- ボルネオールは,Chuanxiong Rhizomaの活性成分の吸収を増加させる.
- ボルネオールは,宿主の脂質代謝を調節し,クアンション・リゾーマの成分吸収を促進するA.ムシニフィラを豊かにします.
結論:
- SJP治療はSCAD患者における脂質代謝の改善と関連しています.
- A.ムチニフィラのボルネオルの濃縮は,宿主脂質代謝を調節する重要なメカニズムである.
- このメカニズムは,Chuanxiong Rhizomaの活性成分の吸収を促進し,SJPの有効性に貢献します.
関連する概念動画
01:26Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
01:30Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
01:30Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
01:26Coronary Artery Disease II: Pathophysiology
33
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236